ChiCTR2300071680 版本V1.1 版本创建时间2023/07/22 20:08:00 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2300071680 

最近更新日期:

Date of Last Refreshed on:

2023-05-22 15:41:31 

注册时间:

Date of Registration:

2023-05-22 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

基于GLIM APP评估的血管外科住院患者营养状况研究

Public title:

A study of nutritional status of inpatients in vascular surgery based on GLIM APP assessment

注册题目简写:

English Acronym:

研究课题的正式科学名称:

基于GLIM APP评估的血管外科住院患者营养状况研究

Scientific title:

A study of nutritional status of inpatients in vascular surgery based on GLIM APP assessment

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

龙志文 

研究负责人:

刘芯君 

Applicant:

Zhiwen Long 

Study leader:

Xinjun Liu 

申请注册联系人电话:

Applicant telephone:

+86 186 2806 9781

研究负责人电话:

Study leader's
telephone:

+86 186 2806 9781

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

longzhiwen@rplushealth.com

研究负责人电子邮件:

Study leader's E-mail:

21603297@qq.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

成都尚医信息科技有限公司

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

四川省成都市高新区天府大道北段1700号1栋3单元17层1708号

研究负责人通讯地址:

成都市金牛区十二桥路39号

Applicant address:

Global Center, North Section, Tianfu Avenue, Chengdu

Study leader's address:

No. 39, Twelve Bridge Road, Jinniu District, Chengdu

申请注册联系人邮政编码:

Applicant postcode:

610000

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

成都尚医信息科技有限公司

Applicant's institution:

Recovery Plus Inc.

研究负责人所在单位:

成都中医药大学附属医院

Affiliation of the Leader:

Hospital of Chengdu University of TMC

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2023KL-012

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

成都中医药大学附属医院医学伦理委员会

Name of the ethic committee:

Ethics Committee of Hospital of Chengdu University of TCM

伦理委员会批准日期:

Date of approved by ethic committee:

2023-03-22 00:00:00

伦理委员会联系人:

马喜桃

Contact Name of the ethic committee:

Xitao Ma

伦理委员会联系地址:

成都市金牛区十二桥路39号

Contact Address of the ethic committee:

No. 39, Twelve Bridge Road, Jinniu District, Chengdu

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 28 8778 3129

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

成都中医药大学附属医院

Primary sponsor:

Hospital of Chengdu University of TMC

研究实施负责(组长)单位地址:

成都市金牛区十二桥路39号

Primary sponsor's address:

No. 39, Twelve Bridge Road, Jinniu District, Chengdu

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

四川

市(区县):

成都

Country:

China

Province:

Sichuan

City:

Chengdu

单位(医院):

成都中医药大学附属医院

具体地址:

成都中医药大学附属医院

Institution
hospital:

Hospital of Chengdu University of TMC

Address:

No. 39, Twelve Bridge Road, Jinniu District, Chengdu

经费或物资来源:

自拟课题

Source(s) of funding:

Self-made program

研究疾病:

血管外科疾病  

Target disease:

vascular surgery disease

研究疾病代码:

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

队列研究 

Study design:

Cohort study 

研究目的:

1. 主要目的:采用 GLIM评估血管外科患者的术前营养状况,为进一步的营养诊断和干预提供参考。 2. 次要目的:通过前瞻性队列研究评估 GLIM标准 在血管外科中评定营养状况的有效性。  

Objectives of Study:

1. Main objective: GLIM was used to evaluate the preoperative nutritional status of vascular surgery patients, and to provide a reference for further nutritional diagnosis and intervention. 2. Secondary objective: To evaluate the effectiveness of GLIM criteria for assessing nutritional status in vascular surgery through a prospective cohort study.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1) 年龄为18-90周岁; 2) 由医生确诊为血管外科疾病; 3) 愿意签署知情同意书。

Inclusion criteria

1) Age is 18-90 years old; 2) Diagnosis of vascular surgical disease by a doctor; 3) Willing to sign informed consent.

排除标准:

1) 不适合做BIA人体成分分析如腹水、水肿、截肢和置有心脏起搏器的病人等 ; 2) 肝功能不全(定义为丙氨酸转氨酶 /天冬氨酸转氨酶高于正常范围 200%或胆红素大于 3mg/dL)或肾功能不全(定义为血肌酐大于 1.5 mg/dL); 3) 妊娠期妇女; 4) 患病资料或随访资料缺失或人体测量指标的信息缺失。

Exclusion criteria:

1) Not suitable for BIA body composition analysis such as ascites, edema, amputation and pacemaker patients; 2) Hepatic insufficiency (defined as alanine aminotransferase/aspartate aminotransferase above 200% normal range or bilirubin greater than 3 mg/dL) or renal insufficiency (defined as serum creatinine greater than 1.5 mg/dL); 3) Pregnant women; 4) Missing disease data or follow-up data or information on anthropometric measures.

研究实施时间:

Study execute time:

From 2023-05-29 00:00:00 To 2024-05-29 00:00:00  

征募观察对象时间:

Recruiting time:

From 2023-05-31 00:00:00 To 2024-02-29 00:00:00

干预措施:

Interventions:

组别:

Case series

样本量:

312

Group:

Case series

Sample size:

干预措施:

干预措施代码:

Intervention:

NA

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

四川 

市(区县):

成都 

Country:

China

Province:

Sichuan

City:

Chengdu

单位(医院):

成都中医药大学附属医院 

单位级别:

三甲 

Institution
hospital:

Hospital of Chengdu University of TMC

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

GLIM评价的营养状况

指标类型:

主要指标

Outcome:

Nutritional status assessed using GLIM

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

NRS2002

指标类型:

主要指标

Outcome:

NRS2002 score

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

住院时长

指标类型:

主要指标

Outcome:

duration of hospital stay

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

术后并发症发生率

指标类型:

主要指标

Outcome:

the rate of complications after discharging from hospital

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

MNA 评分

指标类型:

主要指标

Outcome:

MNA score

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

一个月内再入院率

指标类型:

主要指标

Outcome:

rate of readmission in one month after discharging from hospital

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

灵敏度

指标类型:

次要指标

Outcome:

sensitivity

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

特异度

指标类型:

次要指标

Outcome:

specificity

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

kappa值

指标类型:

次要指标

Outcome:

kappa value

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

阳性预测值

指标类型:

次要指标

Outcome:

PPV

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

阴性预测值

指标类型:

次要指标

Outcome:

NPV

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 90 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

NA

Randomization Procedure (please state who generates the random number sequence and by what method):

NA

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

NA

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

NA

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

采用纸质CRF表格和EDC工具

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Paper-based CRF and EDC tools

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2023-05-22 15:41:07